Kunz, P. L., Graham, N., Catalano, P. J., Nimeiri, H., Fisher, G. A., Longacre, T. A., … Benson, A. B. (2022). A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Kunz, Pamela L., Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre, Carlos J. Suarez, et al. “A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Kunz PL, Graham N, Catalano PJ, Nimeiri H, Fisher GA, Longacre TA, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211). In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Kunz, Pamela L., et al. “A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Kunz PL, Graham N, Catalano PJ, Nimeiri H, Fisher GA, Longacre TA, Suarez CJ, Rubin D, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski M, Schmulbach EL, Reidy DL, Strosberg JR, Wong TZ, O’Dwyer PJ, Benson AB. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211). JOURNAL OF CLINICAL ONCOLOGY. 2022.